Reteplase (Reteplase)
Overview of Reteplase
Reteplase is a parenteral 3rd generation thrombolytic agent. Reteplase is a recombinant plasminogen activator (r-PA), converts plasminogen to plasmin, a proteolytic enzyme which has fibrinolytic properties. It creates a generalised lytic state when administered intravenously. Thus, both protective hemostatic thrombi and target thromboemboli are broken down. Reteplase is indicated in the management of coronary occlusion in acute myocardial infarction (AMI). Reteplase is also used for the treatment of multiple pulmonary emboli that are not massive enough to require surgical management and in cases of central deep vein thrombosis. It was approved by FDA in october, 1996.
Indication of Reteplase
Reteplase is primarily indicated in conditions like Acute myocardial infarction.
Contraindication of Reteplase
No data regarding the contra indications of Reteplase is available.
Side Effects of Reteplase
Reteplase produces potentially life-threatening effects which include Ventricular fibrillation, Arrhythmias, Cardiac Arrest, Pericarditis, Ventricular tachycardia. which are responsible for the discontinuation of Reteplase therapy.,The symptomatic adverse reactions produced by Reteplase are more or less tolerable and if they become severe, they can be treated symptomatically, these include Tachycardia, Bleeding, Cardiac failure, Intracranial hemorrhage.
Precautions of Reteplase
This medication may cause bleeding. Use caution with sharp objects like safety razors or nail cutters and avoid activities which that may increase your chance of getting cut, bruised, or injured. Also, avoid unnecessary injections into the muscles (IM). Caution is advised when using this drug in the elderly because they may be more sensitive to the effects of the drug. This medication should be used only when clearly needed during pregnancy.